Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 7/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | CCR8 | P51685 | 1/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5020379 | 0.88 | SMN1; SMN2 (0.40) | TBXA2RHSP90AA1CYP4F2CYP4A11NPC1 | |
| SCHEMBL5020366 | 0.88 | CCR1 (0.41) | HSP90AA1CYP4F2CYP4A11NPC1LMNA | |
| SCHEMBL5020217 | 0.87 | HSP90AA1 (0.34) | HSP90AA1CYP4F2CYP4A11NPC1LMNA | |
| SCHEMBL5020444 | 0.85 | NPC1 (0.36) | TBXA2RHSP90AA1CYP4F2CYP4A11NPC1 | |
| SCHEMBL5020448 | 0.84 | HSP90AA1 (0.34) | HSP90AA1CYP4F2CYP4A11NPC1LMNA | |
| SCHEMBL5020449 | 0.84 | MEN1 (0.37) | TBXA2RCYP4F2CYP4A11NPC1LMNA | |
| SCHEMBL5020377 | 0.83 | HSP90AA1 (0.34) | TBXA2RHSP90AA1CYP4F2CYP4A11NPC1 | |
| SCHEMBL5020445 | 0.82 | GABRA1 (0.37) | HSP90AA1CYP4F2CYP4A11 | |
| SCHEMBL5020446 | 0.81 | PIK3CA (0.34) | TBXA2RCYP4F2CYP4A11NPC1LMNA | |
| SCHEMBL5020365 | 0.81 | CCR1 (0.35) | HSP90AA1KCNH2CCR1CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140045873-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2014-02-13 | — | — | US | disclosed |
| US-20140045873-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045873-A1 | NOVEL MICROBIOCIDES | MSR1, CD209, C3AR1 | TBXA2R 971/4885HSP90AA1 1228/4885CYP2D6 1420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.